Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

To Meet Or Not To Meet? That Is CDER’s Question As Cmte. Cancellations Rise

Executive Summary

Clinical development and regulatory review are already full of uncertainties, but this year FDA introduced a new twist - canceling and postponing advisory committee meetings. Almost half of the scheduled meetings have not taken place, which may or may not be a bad sign for industry

You may also be interested in...



Will Vytorin Fallout Include ENHANCEd Reporting Requirements For All Trials?

Companies in heavily regulated industries such as pharmaceuticals often describe congressional investigations under the category of "headline risks": They produce a lot of bad press and a lot of work for the legal, public relations and lobbying arms, but their impact on the core functions of developing and selling drugs is limited

Will Vytorin Fallout Include ENHANCEd Reporting Requirements For All Trials?

Companies in heavily regulated industries such as pharmaceuticals often describe congressional investigations under the category of "headline risks": They produce a lot of bad press and a lot of work for the legal, public relations and lobbying arms, but their impact on the core functions of developing and selling drugs is limited

Firazyr advisory committee canceled

Jerini's hereditary angiodema treatment Firazyr (icatibant) will not undergo a review by FDA's Pulmonary-Allergy Drugs Advisory Committee, the firm says Jan. 8. The panel was scheduled to meet Feb. 20 to discuss the orphan drug candidate, which has an April 26 user fee date under priority review...

UsernamePublicRestriction

Register

PS049418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel